30 results on '"Paitazoglou, Christina"'
Search Results
2. Lack of correlation between different congestion markers in acute decompensated heart failure
- Author
-
Haag, Svenja, Jobs, Alexander, Stiermaier, Thomas, Fichera, Carlo-Federico, Paitazoglou, Christina, Eitel, Ingo, Desch, Steffen, and Thiele, Holger
- Published
- 2023
- Full Text
- View/download PDF
3. The ALSTER-FLX Registry: 3-Month outcomes after left atrial appendage occlusion using a next-generation device, a matched-pair analysis to EWOLUTION
- Author
-
Paitazoglou, Christina, Meincke, Felix, Bergmann, Martin W., Eitel, Ingo, Fink, Thomas, Vireca, Elisa, Wohlmuth, Peter, Veliqi, Egzon, Willems, Stephan, Markiewicz, Agata, and Grygier, Marek
- Published
- 2022
- Full Text
- View/download PDF
4. Atrial Mechanics, Atrial Cardiomyopathy and Impact of Atrial Interventions.
- Author
-
KITTIPIBUL, VERAPRAPAS, LAUFER-PERL, MICHAL, BALAKUMARAN, KATHIR, COSTANZO, MARIA ROSA, MARWICK, THOMAS H., ALENEZI, FAWAZ, MOHAN, RAJEEV C., THOHAN, VINAY, BHATT, KUNJAN, FRIEDMANN, ROBERTO HODARA, SMART, FRANK, ECKMAN, PETER M., SARAON, TAJINDERPAL, BIEGUS, JAN, PAITAZOGLOU, CHRISTINA, HAMID, NADIRA, AMIN, ROHIT, TONG, ANN, and FUDIM, MARAT
- Abstract
• Atria make both active and passive contributions throughout the cardiac cycle. • Atrial cardiomyopathy is gaining recognition in various cardiac conditions and is associated with worse prognosis. • Alterations in atrial mechanics are associated with incident heart failure and atrial fibrillation. • Atrial interventions may have adverse subclinical effects on atrial mechanics, which could ultimately result in overt clinical symptoms. • Standardized assessment of atrial mechanics following atrial interventions might allow early detection and prevention of irreversible atrial remodeling. Our comprehension of atrial mechanics, atrial cardiomyopathy and their clinical implications across various cardiovascular conditions has advanced significantly. Atrial interventions can have differing effects on atrial mechanics. With the rapid increase in the use of atrial interventions, it is crucial for investigators and clinicians to acknowledge the potential adverse effects of these interventions on atrial mechanics that might not be clinically significant at the time of interventions. Recognizing the preclinical stage of atrial maladaptation might enable early interventions before the development of irreversible atrial remodeling and clinical manifestation. We review normal atrial function and mechanics, and atrial cardiomyopathy in select cardiovascular conditions. We also summarize and discuss the current evidence of the impact of various atrial interventions on atrial function and mechanics. [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
5. Predictors of Device-Related Thrombus Following Percutaneous Left Atrial Appendage Occlusion
- Author
-
Simard, Trevor, Jung, Richard G., Lehenbauer, Kyle, Piayda, Kerstin, Pracoń, Radoslaw, Jackson, Gregory G., Flores-Umanzor, Eduardo, Faroux, Laurent, Korsholm, Kasper, Chun, Julian K.R., Chen, Shaojie, Maarse, Moniek, Montrella, Kristi, Chaker, Zakeih, Spoon, Jocelyn N., Pastormerlo, Luigi E., Meincke, Felix, Sawant, Abhishek C., Moldovan, Carmen M., Qintar, Mohammed, Aktas, Mehmet K., Branca, Luca, Radinovic, Andrea, Ram, Pradhum, El-Zein, Rayan S., Flautt, Thomas, Ding, Wern Yew, Sayegh, Bassel, Benito-González, Tomás, Lee, Oh-Hyun, Badejoko, Solomon O., Paitazoglou, Christina, Karim, Nabeela, Zaghloul, Ahmed M., Agrawal, Himanshu, Kaplan, Rachel M., Alli, Oluseun, Ahmed, Aamir, Suradi, Hussam S., Knight, Bradley P., Alla, Venkata M., Panaich, Sidakpal S., Wong, Tom, Bergmann, Martin W., Chothia, Rashaad, Kim, Jung-Sun, Pérez de Prado, Armando, Bazaz, Raveen, Gupta, Dhiraj, Valderrabano, Miguel, Sanchez, Carlos E., El Chami, Mikhael F., Mazzone, Patrizio, Adamo, Marianna, Ling, Fred, Wang, Dee Dee, O’Neill, William, Wojakowski, Wojtek, Pershad, Ashish, Berti, Sergio, Spoon, Daniel, Kawsara, Akram, Jabbour, George, Boersma, Lucas V.A., Schmidt, Boris, Nielsen-Kudsk, Jens Erik, Rodés-Cabau, Josep, Freixa, Xavier, Ellis, Christopher R., Fauchier, Laurent, Demkow, Marcin, Sievert, Horst, Main, Michael L., Hibbert, Benjamin, Holmes, David R., Jr., and Alkhouli, Mohamad
- Published
- 2021
- Full Text
- View/download PDF
6. Treatment With an Interatrial Shunt in Heart Failure
- Author
-
Paitazoglou, Christina, primary, Bergmann, Martin W., additional, Kilicaslan, Baris, additional, Kilic, Teoman, additional, Bartunek, Jozef, additional, Pfister, Roman, additional, Iliadis, Christos, additional, Kaya, Ergun Baris, additional, and Ozdemir, Ramazan, additional
- Published
- 2024
- Full Text
- View/download PDF
7. Persistent and Recurrent Device-Related Thrombus After Left Atrial Appendage Closure
- Author
-
Mesnier, Jules, primary, Simard, Trevor, additional, Jung, Richard G., additional, Lehenbauer, Kyle R., additional, Piayda, Kerstin, additional, Pracon, Radoslaw, additional, Jackson, Gregory G., additional, Flores-Umanzor, Eduardo, additional, Faroux, Laurent, additional, Korsholm, Kasper, additional, Chun, Julian K.R., additional, Chen, Shaojie, additional, Maarse, Moniek, additional, Montrella, Kristi, additional, Chaker, Zakeih, additional, Spoon, Jocelyn N., additional, Pastormerlo, Luigi E., additional, Meincke, Felix, additional, Sawant, Abhishek C., additional, Moldovan, Carmen M., additional, Qintar, Mohammed, additional, Aktas, Mehmet K., additional, Branca, Luca, additional, Radinovic, Andrea, additional, Ram, Pradhum, additional, El-Zein, Rayan S., additional, Flautt, Thomas, additional, Ding, Wern Yew, additional, Sayegh, Bassel, additional, Benito-González, Tomás, additional, Lee, Oh-Hyun, additional, Badejoko, Solomon O., additional, Paitazoglou, Christina, additional, Karim, Nabeela, additional, Zaghloul, Ahmed M., additional, Agarwal, Himanshu, additional, Kaplan, Rachel M., additional, Alli, Oluseun, additional, Ahmed, Aamir, additional, Suradi, Hussam S., additional, Knight, Bradley P., additional, Alla, Venkata M., additional, Panaich, Sidakpal S., additional, Wong, Tom, additional, Bergmann, Martin W., additional, Chothia, Rashaad, additional, Kim, Jung-Sun, additional, Pérez de Prado, Armando, additional, Bazaz, Raveen, additional, Gupta, Dhiraj, additional, Valderrábano, Miguel, additional, Sanchez, Carlos E., additional, El Chami, Mikhael F., additional, Mazzone, Patrizio, additional, Adamo, Marianna, additional, Ling, Fred, additional, Wang, Dee Dee, additional, O’Neill, William, additional, Wojakowski, Wojtek, additional, Pershad, Ashish, additional, Berti, Sergio, additional, Spoon, Daniel B., additional, Kawsara, Akram, additional, Jabbour, George, additional, Boersma, Lucas V.A., additional, Schmidt, Boris, additional, Nielsen-Kudsk, Jens Erik, additional, Freixa, Xavier, additional, Ellis, Christopher R., additional, Fauchier, Laurent, additional, Demkow, Marcin, additional, Sievert, Horst, additional, Main, Michael L., additional, Hibbert, Benjamin, additional, Holmes, David R., additional, Alkhouli, Mohamad, additional, and Rodés-Cabau, Josep, additional
- Published
- 2023
- Full Text
- View/download PDF
8. Predicted impact of atrial flow regulator on survival in heart failure with reduced and preserved ejection fraction
- Author
-
Lauder, Lucas, primary, Bergmann, Martin W., additional, Paitazoglou, Christina, additional, Özdemir, Ramazan, additional, Iliadis, Christos, additional, Bartunek, Jozef, additional, Lauten, Alexander, additional, Keller, Thomas, additional, Weber, Stephan, additional, Sievert, Horst, additional, Anker, Stefan D., additional, and Mahfoud, Felix, additional
- Published
- 2023
- Full Text
- View/download PDF
9. PO-03-135 LEFT ATRIAL APPENDAGE OCCLUSION VERSUS STANDARD OF CARE IN PATIENTS WITH ATRIAL FIBRILLATION AND A PRIOR THROMBO-EMBOLIC EVENT DESPITE ORAL ANTICOAGULANT THERAPY: A PROPENSITY SCORE MATCHED COMPARISON
- Author
-
Maarse, Moniek, primary, Seiffge, David, additional, Aarnink, Errol, additional, Fierro, Nicolai, additional, Mazzone, Patrizio, additional, Beneduce, Alessandro, additional, Gasperetti, Alessio, additional, Tondo, Claudio, additional, Pracon, Radek, additional, Demkow, Marcin, additional, Zielinski, Kamil, additional, de Backer, Ole, additional, Korsholm, Kasper, additional, Nielsen-Kudsk, Jens Erik, additional, Estevez-Loureiro, Rodrigo, additional, Benito-Gonzalez, Tomas, additional, Nombela-Franco, Luis, additional, Simard, Trevor, additional, Alkhouli, Mohamad, additional, Holmes, David R., additional, Romeo, Maria Rita, additional, Berti, Sergio, additional, Millan, Xavier, additional, Arzamendi, Dabit, additional, Alla, Venkata M., additional, Paitazoglou, Christina, additional, Eitel, Ingo, additional, Freixa-Rofastes, Xavier, additional, Badejoko, Solomon, additional, Chothia, Rashaad A., additional, Kilic, Özlem, additional, Bergmann, Martin, additional, Spoon, Daniel, additional, Ram, Pradhum, additional, El-Chami, Mikhael F., additional, Branca, Luca, additional, Adamo, Marianna, additional, Danley, Kelsey, additional, Suradi, Hussam, additional, Swaans, Martin, additional, Werring, David, additional, and Boersma, Lucas V., additional
- Published
- 2023
- Full Text
- View/download PDF
10. Hemodynamic Assessment in Takotsubo Syndrome
- Author
-
Stiermaier, Thomas, primary, Reil, Jan-Christian, additional, Sequeira, Vasco, additional, Rawish, Elias, additional, Mezger, Matthias, additional, Pätz, Toni, additional, Paitazoglou, Christina, additional, Schmidt, Tobias, additional, Frerker, Christian, additional, Steendijk, Paul, additional, Reil, Gert-Hinrich, additional, and Eitel, Ingo, additional
- Published
- 2023
- Full Text
- View/download PDF
11. Effect of allogeneic adipose tissue derived mesenchymal stromal cell treatment in chronic ischemic heart failure with reduced ejection fraction – The SCIENCE Trial
- Author
-
Qayyum, Abbas Ali, Van Klarenbosch, Bas, Frljak, Sabina, Cerar, Andraz, Poglajen, Gregor, Traxler‐weidenauer, Denise, Nadrowski, Pawel, Paitazoglou, Christina, Vrtovec, Bojan, Bergmann, Martin W., Chamuleau, Steven A.j., Wojakowski, Wojtek, Gyöngyösi, Mariann, Kraaijeveld, Adriaan, Hansen, Kristian Schultz, Vrangbæk, Karsten, Jørgensen, Erik, Helqvist, Steffen, Joshi, Francis Richard, Johansen, Ellen Mønsted, Follin, Bjarke, Juhl, Morten, Højgaard, Lisbeth Drozd, Mathiasen, Anders Bruun, Ekblond, Annette, Haack‐sørensen, Mandana, Kastrup, Jens, Qayyum, Abbas Ali, Van Klarenbosch, Bas, Frljak, Sabina, Cerar, Andraz, Poglajen, Gregor, Traxler‐weidenauer, Denise, Nadrowski, Pawel, Paitazoglou, Christina, Vrtovec, Bojan, Bergmann, Martin W., Chamuleau, Steven A.j., Wojakowski, Wojtek, Gyöngyösi, Mariann, Kraaijeveld, Adriaan, Hansen, Kristian Schultz, Vrangbæk, Karsten, Jørgensen, Erik, Helqvist, Steffen, Joshi, Francis Richard, Johansen, Ellen Mønsted, Follin, Bjarke, Juhl, Morten, Højgaard, Lisbeth Drozd, Mathiasen, Anders Bruun, Ekblond, Annette, Haack‐sørensen, Mandana, and Kastrup, Jens
- Abstract
Background and Aims The aim of the SCIENCE trial was to investigate whether a single treatment with direct intramyocardial injections of adipose tissue derived mesenchymal stromal cells (CSCC_ASCs) was safe and improved cardiac function in patients with chronic ischemic heart failure with reduced ejection fraction (HFrEF). Methods The study was a European multi-centre double-blinded placebo-controlled phase II trial using allogeneic CSCC_ASCs from healthy donors or placebo (2:1 randomization). Main inclusion criteria were NYHA II-III, left ventricular ejection fraction (LVEF) < 45%, and NT-ProBNP levels>300 pg/mL. CSCC_ASCs or placebo (isotonic saline) were injected directly into viable myocardium. Primary endpoint was change in left ventricular end-systolic volume (LVESV) at 6 months follow up measured by echocardiography. Results A total of 133 symptomatic HFrEF patients were included. The treatment was safe without any drug-related severe adverse events or difference in cardiac related adverse events during a 3-years follow-up period. There were no significant differences between the groups during follow up in LVESV (0.3 ± 5.0 ml, P = 0.945), nor in secondary endpoints left ventricular end-diastolic volume (−2.0 ± 6.0 ml, P = 0.736) and LVEF (−1.6 ± 1.0%, P = 0.119). The NYHA classification improved slightly within the first year in both groups without any difference between groups. There were no changes in 6-Minute Walk Test, NT-ProBNP, CRP or quality-of-life the first year in any of the two groups. Conclusion The SCIENCE trial demonstrated safety of intramyocardial allogeneic CSCC_ASC therapy in patients with chronic HFrEF. However, it was not possible to improve the predefined endpoints and induce restoration of cardiac function or clinical symptoms, Aims The aim of the SCIENCE trial was to investigate whether a single treatment with direct intramyocardial injections of adipose tissue-derived mesenchymal stromal cells (CSCC_ASCs) was safe and improved cardiac function in patients with chronic ischaemic heart failure with reduced ejection fraction (HFrEF). Methods and results The study was a European multicentre, double-blind, placebo-controlled phase II trial using allogeneic CSCC_ASCs from healthy donors or placebo (2:1 randomization). Main inclusion criteria were New York Heart Association (NYHA) class II–III, left ventricular ejection fraction (LVEF) <45%, and N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels >300 pg/ml. CSCC_ASCs or placebo (isotonic saline) were injected directly into viable myocardium. The primary endpoint was change in left ventricular end-systolic volume (LVESV) at 6-month follow-up measured by echocardiography. A total of 133 symptomatic HFrEF patients were included. The treatment was safe without any drug-related severe adverse events or difference in cardiac-related adverse events during a 3-year follow-up period. There were no significant differences between groups during follow-up in LVESV (0.3 ± 5.0 ml, p = 0.945), nor in secondary endpoints of left ventricular end-diastolic volume (−2.0 ± 6.0 ml, p = 0.736) and LVEF (−1.6 ± 1.0%, p = 0.119). The NYHA class improved slightly within the first year in both groups without any difference between groups. There were no changes in 6-min walk test, NT-proBNP, C-reactive protein or quality of life the first year in any groups. Conclusion The SCIENCE trial demonstrated safety of intramyocardial allogeneic CSCC_ASC therapy in patients with chronic HFrEF. However, it was not possible to improve the pre-defined endpoints and induce restoration of cardiac function or clinical symptoms.
- Published
- 2023
12. Sex‐related differences in outcome after left atrial appendage occlusion: Insights from Europe and the EWOLUTION registry.
- Author
-
Paitazoglou, Christina, Eitel, Ingo, Stiermaier, Thomas, Ince, Hueseyin, Kische, Stephan, Pokushalov, Evgeny, Schmitz, Thomas, Schmidt, Boris, Gori, Tommaso, Meincke, Felix, Vireca, Elisa, Wohlmuth, Peter, Lucas, Boersma, and Bergmann, Martin W.
- Published
- 2023
- Full Text
- View/download PDF
13. Left atrial appendage closure in end‐stage renal disease and hemodialysis: Data from a German multicenter registry
- Author
-
Fink, Thomas, primary, Paitazoglou, Christina, additional, Bergmann, Martin W., additional, Sano, Makoto, additional, Keelani, Ahmad, additional, Sciacca, Vanessa, additional, Saad, Mohammed, additional, Eitel, Charlotte, additional, Heeger, Christian‐Hendrik, additional, Skurk, Carsten, additional, Landmesser, Ulf, additional, Thiele, Holger, additional, Stiermaier, Thomas, additional, Fuernau, Georg, additional, Reil, Jan‐Christian, additional, Frey, Norbert, additional, Kuck, Karl‐Heinz, additional, Tilz, Roland R., additional, Sandri, Marcus, additional, and Eitel, Ingo, additional
- Published
- 2023
- Full Text
- View/download PDF
14. Atrial Giant Cell Myocarditis as a Cause of Heart Failure
- Author
-
Paitazoglou, Christina, Bergmann, Martin W., Tiemann, Katharina, Wiese, Andrea, Schäfer, Ulrich, Schwarz, Arne, Eitel, Ingo, and Montenbruck, Moritz
- Subjects
atrial giant cell myocarditis ,AF, atrial fibrillation ,RA, right atrium ,heart failure ,Case Report ,TEE, transesophageal echocardiography ,HF, heart failure ,Ig, immunoglobulin ,LA, left atrium ,cardiac magnetic resonance ,Clinical Case ,CMR, cardiac magnetic resonance ,ANCA, antineutrophil cytoplasmic antibody ,cardiovascular system ,magnetic resonance imaging ,GCM, giant cell myocarditis ,Cardiology and Cardiovascular Medicine - Abstract
We present a patient with acute heart failure and new onset atrial fibrillation secondary to giant cell myocarditis with lone atrial involvement. The diagnosis was managed with cardiac magnetic resonance and confirmed by interventionally guided biopsy. In the future, diagnosis could be managed noninvasively for this rare entity as the gold standard. (Level of Difficulty: Advanced.), Graphical abstract
- Published
- 2022
15. Predictors of Device-Related Thrombus Following Percutaneous Left Atrial Appendage Occlusion
- Author
-
Fauchier, Grégoire, Bisson, Arnaud, Bodin, Alexandre, Herbert, Julien, Semaan, Carl, Angoulvant, Denis, Ducluzeau, Pierre Henri, Lip, Gregory, Fauchier, Laurent, Deharo, Pierre, Cuisset, Thomas, Lacour, Thibaud, Etienne, Christophe Saint, Jaussaud, Nicolas, Morera, Pierre, Spychaj, Jean-Charles, Porto, Alizée, Collart, Frederic, Theron, Alexis, Bernard, Anne, Bourguignon, Thierry, Simard, Trevor, Jung, Richard, Lehenbauer, Kyle, Piayda, Kerstin, Pracoń, Radoslaw, Jackson, Gregory, Flores-Umanzor, Eduardo, Faroux, Laurent, Korsholm, Kasper, Chun, Julian K.R., Chen, Shaojie, Maarse, Moniek, Montrella, Kristi, Chaker, Zakeih, Spoon, Jocelyn, Pastormerlo, Luigi, Meincke, Felix, Sawant, Abhishek, Moldovan, Carmen, Qintar, Mohammed, Aktas, Mehmet, Branca, Luca, Radinovic, Andrea, Ram, Pradhum, El-Zein, Rayan, Flautt, Thomas, Ding, Wern Yew, Sayegh, Bassel, Benito-González, Tomás, Lee, Oh-Hyun, Badejoko, Solomon, Paitazoglou, Christina, Karim, Nabeela, Zaghloul, Ahmed, Agrawal, Himanshu, Kaplan, Rachel, Alli, Oluseun, Ahmed, Aamir, Suradi, Hussam, Knight, Bradley, Alla, Venkata, Panaich, Sidakpal, Wong, Tom, Bergmann, Martin, Chothia, Rashaad, Kim, Jung-Sun, Pérez de Prado, Armando, Bazaz, Raveen, Gupta, Dhiraj, Valderrabano, Miguel, Sanchez, Carlos, El Chami, Mikhael, Mazzone, Patrizio, Adamo, Marianna, Ling, Fred, Wang, Dee Dee, O’neill, William, Wojakowski, Wojtek, Pershad, Ashish, Berti, Sergio, Spoon, Daniel, Kawsara, Akram, Jabbour, George, Boersma, Lucas V.A., Schmidt, Boris, Nielsen-Kudsk, Jens Erik, Rodés-Cabau, Josep, Freixa, Xavier, Ellis, Christopher, Demkow, Marcin, Sievert, Horst, Main, Michael, Hibbert, Benjamin, Holmes, David, Alkhouli, Mohamad, Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), CHU Trousseau [Tours], Éducation Éthique Santé EA 7505 (EES), Université de Tours (UT), EA4245 - Transplantation, Immunologie, Inflammation [Tours] (T2i), University of Liverpool, Aalborg University [Denmark] (AAU), Centre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research (C2VN), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Hôpital de la Timone [CHU - APHM] (TIMONE), Nutrition, obésité et risque thrombotique (NORT), Institut National de la Recherche Agronomique (INRA)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Marseille, Département de Cardiologie [Hôpital de la Timone - APHM], Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), Institut de neurophysiopathologie (INP), Aix Marseille Université (AMU)-Centre National de la Recherche Scientifique (CNRS), University of Ottawa [Ottawa], Université Laval [Québec] (ULaval), National Institute for Research and Development in Microtechnologies (IMT-Bucharest), Graduate School, Cardiology, and ACS - Heart failure & arrhythmias
- Subjects
Male ,Cardiac Catheterization ,Time Factors ,Percutaneous ,left atrial appendage occlusion ,Septal Occluder Device ,medicine.medical_treatment ,Transesophageal ,[SHS]Humanities and Social Sciences ,Pulmonary vein ,Postoperative Complications ,Risk Factors ,Interquartile range ,Atrial Fibrillation ,Registries ,Embolization ,ComputingMilieux_MISCELLANEOUS ,Watchman ,Incidence ,Atrial fibrillation ,Europe ,Survival Rate ,Treatment Outcome ,Echocardiography ,Cardiology ,Female ,Watchman FLX ,Cardiology and Cardiovascular Medicine ,medicine.medical_specialty ,Heart Diseases ,ACP ,Amplatzer cardiac plug ,Amulet ,DRT ,LAAO ,device-related thrombus ,Aged ,Atrial Appendage ,Echocardiography, Transesophageal ,Follow-Up Studies ,Humans ,Thrombosis ,Left atrial appendage occlusion ,Internal medicine ,medicine ,Risk factor ,Thrombus ,business.industry ,medicine.disease ,business - Abstract
Background: Device-related thrombus (DRT) has been considered an Achilles’ heel of left atrial appendage occlusion (LAAO). However, data on DRT prediction remain limited. Objectives: This study constructed a DRT registry via a multicenter collaboration aimed to assess outcomes and predictors of DRT. Methods: Thirty-seven international centers contributed LAAO cases with and without DRT (device-matched and temporally related to the DRT cases). This study described the management patterns and mid-term outcomes of DRT and assessed patient and procedural predictors of DRT. Results: A total of 711 patients (237 with and 474 without DRT) were included. Follow-up duration was similar in the DRT and no-DRT groups, median 1.8 years (interquartile range: 0.9-3.0 years) versus 1.6 years (interquartile range: 1.0-2.9 years), respectively (P = 0.76). DRTs were detected between days 0 to 45, 45 to 180, 180 to 365, and >365 in 24.9%, 38.8%, 16.0%, and 20.3% of patients. DRT presence was associated with a higher risk of the composite endpoint of death, ischemic stroke, or systemic embolization (HR: 2.37; 95% CI, 1.58-3.56; P < 0.001) driven by ischemic stroke (HR: 3.49; 95% CI: 1.35-9.00; P = 0.01). At last known follow-up, 25.3% of patients had DRT. Discharge medications after LAAO did not have an impact on DRT. Multivariable analysis identified 5 DRT risk factors: hypercoagulability disorder (odds ratio [OR]: 17.50; 95% CI: 3.39-90.45), pericardial effusion (OR: 13.45; 95% CI: 1.46-123.52), renal insufficiency (OR: 4.02; 95% CI: 1.22-13.25), implantation depth >10 mm from the pulmonary vein limbus (OR: 2.41; 95% CI: 1.57-3.69), and non-paroxysmal atrial fibrillation (OR: 1.90; 95% CI: 1.22-2.97). Following conversion to risk factor points, patients with ≥2 risk points for DRT had a 2.1-fold increased risk of DRT compared with those without any risk factors. Conclusions: DRT after LAAO is associated with ischemic events. Patient- and procedure-specific factors are associated with the risk of DRT and may aid in risk stratification of patients referred for LAAO.
- Published
- 2021
16. Lack of correlation between different congestion markers in acute decompensated heart failure
- Author
-
Haag, Svenja, primary, Jobs, Alexander, additional, Stiermaier, Thomas, additional, Fichera, Carlo-Federico, additional, Paitazoglou, Christina, additional, Eitel, Ingo, additional, Desch, Steffen, additional, and Thiele, Holger, additional
- Published
- 2022
- Full Text
- View/download PDF
17. Intramyocardial injections of erythropoietin-analogue C.E.R.A. in ischemic cardiomyopathy: the ALSTER C.E.R.A. trial
- Author
-
Paitazoglou, Christina, primary, Bergmann, Martin W., additional, Losik, Denis, additional, Pokushalov, Evgeny, additional, Shabanov, Vitaly, additional, and Romanov, Alexander, additional
- Published
- 2022
- Full Text
- View/download PDF
18. One-year results of the first-in-man study investigating the Atrial Flow Regulator for left atrial shunting in symptomatic heart failure patients: the PRELIEVE study
- Author
-
Paitazoglou, Christina, Bergmann, Martin W., Ozdemir, Ramazan, Pfister, Roman, Bartunek, Jozef, Kilic, Teoman, Lauten, Alexander, Schmeisser, Alexander, Zoghi, Mehdi, Anker, Stefan D., Sievert, Horst, Mahfoud, Felix, Paitazoglou, Christina, Bergmann, Martin W., Ozdemir, Ramazan, Pfister, Roman, Bartunek, Jozef, Kilic, Teoman, Lauten, Alexander, Schmeisser, Alexander, Zoghi, Mehdi, Anker, Stefan D., Sievert, Horst, and Mahfoud, Felix
- Abstract
Aims Attenuating exercise-induced elevated left atrial pressure with an atrial shunt device is under clinical investigation for treatment of symptomatic heart failure (HF). Methods and results PRELIEVE was a prospective, non-randomised, multicentre, first-in-man study in symptomatic HF patients with reduced (HFrEF) or preserved (HFpEF) ejection fraction and pulmonary capillary wedge pressure (PCWP) >= 15 mmHg at rest or >= 25 mmHg during exercise. Here, we provide follow-up data up to 1 year after implantation of the Atrial Flow Regulator (AFR) device. The AFR was successfully implanted in 53 patients (HFrEF n = 24 and HFpEF n = 29). Two patients were not enrolled due to an unsuccessful transseptal puncture. There was one device embolisation into the left atrium, which required surgical removal. One patient experienced a serious procedure-related adverse event (post-procedural bleeding and syncope). All patients with sufficient echocardiography readout confirmed device patency with left-right shunt both at 3 (n = 47/51, 92%) and 12 (n = 45/49, 92%) months. At 3 months, rest PCWP decreased by 5 (-12, 0) mmHg (P = 0.0003, median Q1, Q3). No patient developed a stroke, worsening of right heart function or significant increase of pulmonary artery pressure. Six (6/53, 11%) patients were hospitalised for worsening of HF and three (3/53, 6%) patients died. We observed improvements in New York Heart Association functional class, 6-min walking distance and quality of life (Kansas City Cardiomyopathy Questionnaire) in certain patients. Conclusions Implantation of the AFR device in HF patients was feasible. No shunt occlusion, stroke or new right HF was observed during the 1-year follow-up, with clinical improvements in certain patients.
- Published
- 2021
19. True Efficacy of LAA Closure: Patient Outcomes on Long-term Single-Antiplatelet or No Therapy: Insights From the EWOLUTION Registry.
- Author
-
Paitazoglou, Christina, Bergmann, Martin W., Ince, Hüseyin, Kische, Stephan, Romanov, Aleksandr, Schmitz, Thomas, Schmidt, Boris, Gori, Tommaso, Meincke, Felix, Protopopov, Alexey Vladimir, Betts, Timothy, Vireca, Elisa, Wohlmuth, Peter, and Boersma, Lucas
- Published
- 2022
- Full Text
- View/download PDF
20. The atrial flow regulator: current overview on technique and first experience
- Author
-
Paitazoglou, Christina, primary and Bergmann, Martin W., additional
- Published
- 2020
- Full Text
- View/download PDF
21. Early Transendocardial Autologous Bone Marrow Injection of Bone Marrow Derived Mononuclear Cells following Ischemic Myocardial Events: The Alster-Helix Registry
- Author
-
Paitazoglou, Christina, Christian-H Heeger, Thiele, Holger, Jaquet, Kai, Karl-Heinz Kuck, Boosfeld, Christoph, Altman, Peter, and Bergmann, Martin W
- Published
- 2019
- Full Text
- View/download PDF
22. The AFR-PRELIEVE trial: a prospective, non-randomised, pilot study to assess the Atrial Flow Regulator (AFR) in heart failure patients with either preserved or reduced ejection fraction
- Author
-
Paitazoglou, Christina, Ozdemir, Ramazan, Pfister, Roman, Bergmann, Martin W., Bartunek, Jozef, Kilic, Teoman, Lauten, Alexander, Schmeisser, Alexander, Zoghi, Mehdi, Anker, Stefan, Sievert, Horst, Mahfoud, Felix, Paitazoglou, Christina, Ozdemir, Ramazan, Pfister, Roman, Bergmann, Martin W., Bartunek, Jozef, Kilic, Teoman, Lauten, Alexander, Schmeisser, Alexander, Zoghi, Mehdi, Anker, Stefan, Sievert, Horst, and Mahfoud, Felix
- Abstract
Aims: Reducing elevated left atrial pressure with an atrial septum shunt device is a possible treatment option in symptomatic heart failure patients. This study aimed to investigate the safety and feasibility of the Atrial Flow Regulator (AFR) in heart failure patients. Methods and results: AFR-PRELIEVE is a prospective, non-randomised, open-label, multicentre study in patients with symptomatic heart failure NYHA Class III or IV and pulmonary capillary wedge pressure (PCWP) >= 15 mmHg at rest or >= 25 mmHg at exercise irrespective of left ventricular ejection fraction (EF >= 15%). Here we report on procedural and three-month follow-up data for a total of thirty-six enrolled patients. Sixteen (44.5%) patients with reduced EF (HFrEF: EF 15-39%) and twenty (55.5%) patients with preserved EF (HFpEF: EF >= 40%) were enrolled. Implantation success rate and device patency with left-right shunt was 100% (post procedure and at three months) in both patient groups, with one SADE in the HFpEF group which completely resolved. Three (3/36, 8.3%) patients were hospitalised for worsening of heart failure (two HFrEF patients, one HFpEF patient). Individual patients from both the HFrEF and HFpEF groups showed improvement in symptoms and surrogate parameters of heart failure (NYHA class, six-minute walking distance, Kansas City Cardiomyopathy Questionnaire, PCWP, NT-proBNP). Conclusions: Implantation of the AFR device in heart failure patients is feasible and safe; shunt patency at three months was confirmed in the study. The atrial shunt improved symptoms and surrogate parameters of heart failure in some but not all patients in both the HFpEF and HFrEF groups.
- Published
- 2019
23. Rationale and design of the European multicentre study on Stem Cell therapy in IschEmic Non-treatable Cardiac diseasE (SCIENCE)
- Author
-
Paitazoglou, Christina, Bergmann, Martin W, Vrtovec, Bojan, Chamuleau, Steven A J, van Klarenbosch, Bas, Wojakowski, Wojtek, Michalewska-Włudarczyk, Aleksandra, Gyöngyösi, Mariann, Ekblond, Annette, Haack-Sørensen, Mandana, Jaquet, Kai, Vrangbæk, Karsten, Kastrup, Jens, Paitazoglou, Christina, Bergmann, Martin W, Vrtovec, Bojan, Chamuleau, Steven A J, van Klarenbosch, Bas, Wojakowski, Wojtek, Michalewska-Włudarczyk, Aleksandra, Gyöngyösi, Mariann, Ekblond, Annette, Haack-Sørensen, Mandana, Jaquet, Kai, Vrangbæk, Karsten, and Kastrup, Jens
- Abstract
AIMS: Ischaemic heart failure (IHF) patients have a poor prognosis even with current guideline-derived therapy. Intramyocardial injections of autologous or allogeneic mesenchymal stromal cells might improve cardiac function leading to better clinical outcome.METHODS: The SCIENCE (Stem Cell therapy in IschEmic Non-treatable Cardiac diseasE) consortium has initiated a Horizon 2020 funded multicentre phase II study in six European countries. It is a double-blind, placebo-controlled trial testing the safety and efficacy of allogeneic Cardiology Stem Cell Centre Adipose-derived Stromal Cells (CSCC_ASC) from healthy donors or placebo in 138 symptomatic IHF patients. Main inclusion criteria are New York Heart Association class II-III, left ventricular ejection fraction < 45% and N-terminal pro-B-type natriuretic peptide levels > 300 pg/mL. Patients are randomized in a 2:1 pattern to receive intramyocardial injections of either CSCC_ASC or placebo. CSCC_ASC and placebo treatments are prepared centralized at Rigshospitalet in 5 mL vials as an off-the-shelf product. Vials are distributed to all clinical partners and stored in nitrogen vapour tanks ready to be used directly after thawing. A total of 100 × 106 CSCC_ASC or placebo are injected directly into viable myocardium in the infarct border zone using the NOGA XP system (BDS, Cordis, Johnson & Johnson, USA). Primary endpoint is a centralized core-laboratory assessed change in left ventricular end-systolic volume at 6-month follow-up measured by echocardiography. The trial started in January 2017, 58 patients were included and treated until July 2018.CONCLUSION: The SCIENCE trial will provide clinical data on efficacy and safety of intramyocardial cell therapy of allogeneic adipose-derived stromal cells from healthy donors in patients with IHF.
- Published
- 2019
24. The ALSTER-TAVI All-Comers Registry: Procedural and 1-Year Clinical Outcomes of Balloon-Expandable vs Self-Expanding Contemporary TAVI Valves.
- Author
-
Paitazoglou, Christina, Meincke, Felix, Hanke, Thorsten, Laß, Michael, Noack, Jan, Grüning, Anna, Frerker, Christian, Goldmann, Britta, Peitsmeyer, Philipp, Schmöckel, Michael, Willems, Stephan, and Bergmann, Martin W.
- Published
- 2021
- Full Text
- View/download PDF
25. The AFR-PRELIEVE trial: a prospective, non-randomised, pilot study to assess the Atrial Flow Regulator (AFR) in heart failure patients with either preserved or reduced ejection fraction
- Author
-
Paitazoglou, Christina, primary, Özdemir, Ramazan, additional, Pfister, Roman, additional, Bergmann, Martin W., additional, Bartunek, Jozef, additional, Kilic, Teoman, additional, Lauten, Alexander, additional, Schmeisser, Alexander, additional, Zoghi, Mehdi, additional, Anker, Stefan, additional, Sievert, Horst, additional, and Mahfoud, Felix, additional
- Published
- 2019
- Full Text
- View/download PDF
26. Left Atrial Appendage Occlusion vs Standard of Care After Ischemic Stroke Despite Anticoagulation.
- Author
-
Maarse M, Seiffge DJ, Werring DJ, Boersma LVA, Aarnink EW, Fierro N, Mazzone P, Beneduce A, Tondo C, Gasperetti A, Pracon R, Demkow M, Zielinski K, de Backer O, Korsholm K, Nielsen-Kudsk JE, Estévez-Loureiro R, Caneiro-Queija B, Benito-González T, de Prado AP, Nombela-Franco L, Salinas P, Holmes D, Almakadma AH, Berti S, Romeo MR, Alvarez XM, Arzamendi D, Alla VM, Agarwal H, Eitel I, Paitazoglou C, Freixa X, Cepas-Guillén P, Chothia R, Badejoko SO, Bergmann MW, Spoon DB, Maddux JT, El-Chami M, Ram P, Branca L, Adamo M, Suradi HS, van Dijk VF, Rensing BJWM, Zietz A, Paciaroni M, Caso V, Koga M, Toyoda K, Kallmünzer B, Cappellari M, Wilson D, Engelter S, and Swaans MJ
- Abstract
Importance: Patients with atrial fibrillation (AF) who have ischemic stroke despite taking oral anticoagulation therapy (OAT) have a very high risk of recurrence. Left atrial appendage occlusion (LAAO) is a mechanical stroke prevention strategy that may provide additional protection in patients with thromboembolic events under OAT., Objective: To compare percutaneous LAAO with continuing OAT alone regarding stroke prevention in patients with AF who had a thromboembolic event despite taking OAT., Design, Setting, and Participants: This cohort study was a propensity score-matched comparison of the STR-OAC LAAO cohort, an international collaboration of 21 sites combining patients from multiple prospective registries of patients who underwent LAAO between 2010 and 2022. STR-OAC LAAO cohort patients who had follow-up longer than 3 months were propensity score-matched to a previously published control cohort comprising patients from an established international collaboration of investigator-initiated prospective studies. This control cohort included patients with nonvalvular AF, recent ischemic stroke or transient ischemic attack, and follow-up longer than 3 months who were taking OAT before the index event. Analyses were adjusted for imbalances in gender, age, hypertension, diabetes, and CHA2 DS2-VASc score., Exposure: Left atrial appendage occlusion vs continuation of oral anticoagulation therapy alone (control group)., Main Outcomes and Measures: The primary outcome was time to first ischemic stroke., Results: Four hundred thirty-three patients from the STR-OAC LAAO cohort (mean [SD] age, 72 [9] years; 171 [39%] females and 262 [61%] males; mean [SD] CHA2 DS2-VASc score, 5.0 [1.6]) were matched to 433 of 1140 patients (38%) from the control group. During 2-year follow-up, 50 patients experienced ischemic stroke: an annualized event rate of 2.8% per patient-year in the STR-OAC LAAO group vs 8.9% per patient-year in the control group. Left atrial appendage occlusion was associated with a lower risk of ischemic stroke (hazard ratio, 0.33; 95% CI, 0.19-0.58; P < .001) compared with the control group. After LAAO, OAT was discontinued in 290 patients (67%), and the remaining 143 patients (33%) continued OAT after LAAO as an adjunctive therapy., Conclusions and Relevance: In patients with nonvalvular AF and a prior thromboembolic event despite taking OAT, LAAO was associated with a lower risk of ischemic stroke compared with continued OAT alone. Randomized clinical trial data are needed to confirm that LAAO may be a promising treatment option for this population with a very high risk of stroke.
- Published
- 2024
- Full Text
- View/download PDF
27. ALSTER-TAVR 2024: clinical results at one year following optimized self-expanding, transcatheter aortic valve peplacement employing the cusp-overlay technique.
- Author
-
Bergmann MW, Krause JM, Schofer N, Meincke F, Paitazoglou C, Heeger CH, Willems S, Hakmi S, and Tigges E
- Abstract
Objectives: Atrioventricular (AV) conduction disturbances are still common following transcatheter aortic valve replacement (TAVR). The study evaluates the feasibility and clinical effect of self-expanding (SE)-TAVR employing an optimized cusp-overlay technique (COT) at 1 year in a German all-comers population., Methods: We analyzed 1-year clinical outcomes in patients who received a SE valve employing the optimized COT. Consecutive patients who underwent SE-TAVR (EvolutR, EvolutPRO) after introduction of the COT as the default implantation technique in 2020 were included (n = 101). Consecutive TAVR patients from the same operators using the conventional implantation technique (CIT) served as the control group (n = 116)., Results: The COT was successfully performed in more than 80% of the patients in the COT group. (81.2%, n = 82/101). At discharge, no difference regarding AV block of at least II (CIT 19.47% vs COT 21%; P = .86) and permanent pacemaker (PPM) implantation (CIT 17.5% vs COT 19%; P = .73) was observed between the cohorts. New left bundle branch block (LBBB) was significantly less frequent in the COT group (CIT 40.71% vs COT 26%; P = .029). Paravalvular leakage (PVL) greater than I° was reduced in the COT cohort (CIT 8.62% vs COT 0.99%; P = .012). There was no significant difference in mortality (CIT 18.27% vs COT 13.83%; P = .44), stroke (CIT 9.62% vs COT 15.96%; P = .16) or cardiovascular rehospitalization after 1 year (CIT 25.96% vs 24.47%; P = .92) between the groups., Conclusions: Implementation of COT-TAVR was feasible and safe, and it resulted in an improvement of TAVR outcomes regarding PVL greater than I° and new onset LBBB. However, with respect to PPM, no difference was observed 1-year post-TAVR.
- Published
- 2024
- Full Text
- View/download PDF
28. Effect of allogeneic adipose tissue-derived mesenchymal stromal cell treatment in chronic ischaemic heart failure with reduced ejection fraction - the SCIENCE trial.
- Author
-
Qayyum AA, van Klarenbosch B, Frljak S, Cerar A, Poglajen G, Traxler-Weidenauer D, Nadrowski P, Paitazoglou C, Vrtovec B, Bergmann MW, Chamuleau SAJ, Wojakowski W, Gyöngyösi M, Kraaijeveld A, Hansen KS, Vrangbaek K, Jørgensen E, Helqvist S, Joshi FR, Johansen EM, Follin B, Juhl M, Højgaard LD, Mathiasen AB, Ekblond A, Haack-Sørensen M, and Kastrup J
- Subjects
- Humans, Chronic Disease, Quality of Life, Stroke Volume, Treatment Outcome, Ventricular Function, Left, Double-Blind Method, Heart Failure, Hematopoietic Stem Cell Transplantation, Mesenchymal Stem Cells
- Abstract
Aims: The aim of the SCIENCE trial was to investigate whether a single treatment with direct intramyocardial injections of adipose tissue-derived mesenchymal stromal cells (CSCC_ASCs) was safe and improved cardiac function in patients with chronic ischaemic heart failure with reduced ejection fraction (HFrEF)., Methods and Results: The study was a European multicentre, double-blind, placebo-controlled phase II trial using allogeneic CSCC_ASCs from healthy donors or placebo (2:1 randomization). Main inclusion criteria were New York Heart Association (NYHA) class II-III, left ventricular ejection fraction (LVEF) <45%, and N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels >300 pg/ml. CSCC_ASCs or placebo (isotonic saline) were injected directly into viable myocardium. The primary endpoint was change in left ventricular end-systolic volume (LVESV) at 6-month follow-up measured by echocardiography. A total of 133 symptomatic HFrEF patients were included. The treatment was safe without any drug-related severe adverse events or difference in cardiac-related adverse events during a 3-year follow-up period. There were no significant differences between groups during follow-up in LVESV (0.3 ± 5.0 ml, p = 0.945), nor in secondary endpoints of left ventricular end-diastolic volume (-2.0 ± 6.0 ml, p = 0.736) and LVEF (-1.6 ± 1.0%, p = 0.119). The NYHA class improved slightly within the first year in both groups without any difference between groups. There were no changes in 6-min walk test, NT-proBNP, C-reactive protein or quality of life the first year in any groups., Conclusion: The SCIENCE trial demonstrated safety of intramyocardial allogeneic CSCC_ASC therapy in patients with chronic HFrEF. However, it was not possible to improve the pre-defined endpoints and induce restoration of cardiac function or clinical symptoms., (© 2023 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.)
- Published
- 2023
- Full Text
- View/download PDF
29. One-year results of the first-in-man study investigating the Atrial Flow Regulator for left atrial shunting in symptomatic heart failure patients: the PRELIEVE study.
- Author
-
Paitazoglou C, Bergmann MW, Özdemir R, Pfister R, Bartunek J, Kilic T, Lauten A, Schmeisser A, Zoghi M, Anker SD, Sievert H, and Mahfoud F
- Subjects
- Cardiac Catheterization, Heart Atria, Humans, Prospective Studies, Quality of Life, Stroke Volume, Heart Failure
- Abstract
Aims: Attenuating exercise-induced elevated left atrial pressure with an atrial shunt device is under clinical investigation for treatment of symptomatic heart failure (HF)., Methods and Results: PRELIEVE was a prospective, non-randomised, multicentre, first-in-man study in symptomatic HF patients with reduced (HFrEF) or preserved (HFpEF) ejection fraction and pulmonary capillary wedge pressure (PCWP) ≥15 mmHg at rest or ≥25 mmHg during exercise. Here, we provide follow-up data up to 1 year after implantation of the Atrial Flow Regulator (AFR) device. The AFR was successfully implanted in 53 patients (HFrEF n = 24 and HFpEF n = 29). Two patients were not enrolled due to an unsuccessful transseptal puncture. There was one device embolisation into the left atrium, which required surgical removal. One patient experienced a serious procedure-related adverse event (post-procedural bleeding and syncope). All patients with sufficient echocardiography readout confirmed device patency with left-right shunt both at 3 (n = 47/51, 92%) and 12 (n = 45/49, 92%) months. At 3 months, rest PCWP decreased by 5 (-12, 0) mmHg (P = 0.0003, median Q1, Q3). No patient developed a stroke, worsening of right heart function or significant increase of pulmonary artery pressure. Six (6/53, 11%) patients were hospitalised for worsening of HF and three (3/53, 6%) patients died. We observed improvements in New York Heart Association functional class, 6-min walking distance and quality of life (Kansas City Cardiomyopathy Questionnaire) in certain patients., Conclusions: Implantation of the AFR device in HF patients was feasible. No shunt occlusion, stroke or new right HF was observed during the 1-year follow-up, with clinical improvements in certain patients., (© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.)
- Published
- 2021
- Full Text
- View/download PDF
30. Rationale and design of the European multicentre study on Stem Cell therapy in IschEmic Non-treatable Cardiac diseasE (SCIENCE).
- Author
-
Paitazoglou C, Bergmann MW, Vrtovec B, Chamuleau SAJ, van Klarenbosch B, Wojakowski W, Michalewska-Włudarczyk A, Gyöngyösi M, Ekblond A, Haack-Sørensen M, Jaquet K, Vrangbaek K, and Kastrup J
- Subjects
- Adult, Aged, Aged, 80 and over, Double-Blind Method, Echocardiography, Europe, Female, Heart Failure diagnosis, Heart Failure physiopathology, Humans, Male, Mesenchymal Stem Cell Transplantation, Middle Aged, Myocardium, Retrospective Studies, Treatment Outcome, Cell- and Tissue-Based Therapy methods, Heart Failure therapy, Stroke Volume physiology, Ventricular Function, Left physiology
- Abstract
Aims: Ischaemic heart failure (IHF) patients have a poor prognosis even with current guideline-derived therapy. Intramyocardial injections of autologous or allogeneic mesenchymal stromal cells might improve cardiac function leading to better clinical outcome., Methods: The SCIENCE (Stem Cell therapy in IschEmic Non-treatable Cardiac diseasE) consortium has initiated a Horizon 2020 funded multicentre phase II study in six European countries. It is a double-blind, placebo-controlled trial testing the safety and efficacy of allogeneic Cardiology Stem Cell Centre Adipose-derived Stromal Cells (CSCC_ASC) from healthy donors or placebo in 138 symptomatic IHF patients. Main inclusion criteria are New York Heart Association class II-III, left ventricular ejection fraction < 45% and N-terminal pro-B-type natriuretic peptide levels > 300 pg/mL. Patients are randomized in a 2:1 pattern to receive intramyocardial injections of either CSCC_ASC or placebo. CSCC_ASC and placebo treatments are prepared centralized at Rigshospitalet in 5 mL vials as an off-the-shelf product. Vials are distributed to all clinical partners and stored in nitrogen vapour tanks ready to be used directly after thawing. A total of 100 × 10
6 CSCC_ASC or placebo are injected directly into viable myocardium in the infarct border zone using the NOGA XP system (BDS, Cordis, Johnson & Johnson, USA). Primary endpoint is a centralized core-laboratory assessed change in left ventricular end-systolic volume at 6-month follow-up measured by echocardiography. The trial started in January 2017, 58 patients were included and treated until July 2018., Conclusion: The SCIENCE trial will provide clinical data on efficacy and safety of intramyocardial cell therapy of allogeneic adipose-derived stromal cells from healthy donors in patients with IHF., (© 2019 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.)- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.